The lawsuit follows a cease-and-desist request and argues Lilly is using “deceptive” ads to claim its GLP-1 products are ...

The study failure costs Agios a chance to one-up Novo Nordisk and represents yet another setback in a disease that’s ...

Bristol Myers is the third pharmaceutical company to recently seek Nvidia’s help building a large AI data center. Elsewhere, ...

BioPharma Dive provides news and analysis for biotech and biopharmaceutical executives. We cover topics like clinical trials, drug discovery and development, pharma marketing, FDA approvals and ...

The Westlake-founded company specializes in non-opioid drugs that target sodium ion channels, and is now adding to what’s ...

Tempus AI’s planned acquisition follows recent interest in blood-based cancer tests across the medtech industry.

The speedy clearance of Lipfendra is an important milestone for Merck and the result of a controversial voucher program put in place by former FDA commissioner Marty Makary.

The latest in a prolific streak of buyouts by Lilly is the strongest sign yet that large pharmaceutical companies may finally ...

The study provides the clearest evidence yet that medicines like BIIB080 might improve cognition, but leaves unclear why ...

Some of the industry’s most closely-watched AI drugs could provide insight into the success of technology-assisted ...

Eplontersen’s failure in transthyretin-mediated amyloidosis cardiomyopathy caught Wall Street analysts by surprise and ...

The acquisition, which involves a concurrent licensing deal with startup Mirador, gives Jasper a chance to rebound from ...